Vyleesi and Finasteride Interaction: Safety, Mechanisms, and Clinical Guidance

Why This Combination Comes Up in Clinical Practice

Patients and clinicians increasingly encounter scenarios where a premenopausal woman using bremelanotide for HSDD has a male partner taking finasteride for hair loss or benign prostatic hyperplasia (BPH). The question also arises in transgender or nonbinary patients whose medication regimens may include both agents. Bremelanotide (brand name Vyleesi) received FDA approval in June 2019 for HSDD in premenopausal women, while finasteride has been available since 1992 for BPH at 5 mg daily and since 1997 for male androgenetic alopecia at 1 mg daily [1,2]. Neither label lists the other drug as a contraindication or precaution. Sexual function side effects from finasteride, including decreased libido in 1.8% of men in the original PLESS trial (N=3,040), sometimes prompt household-level questions about whether bremelanotide could offset those effects [3].

Pharmacokinetic Profile of Bremelanotide

Bremelanotide's metabolism makes CYP-mediated interactions unlikely. The drug is a cyclic heptapeptide that undergoes hydrolysis into multiple metabolite fragments rather than oxidative metabolism through cytochrome P450 enzymes [1]. According to the Vyleesi prescribing information, bremelanotide is not a substrate, inhibitor, or inducer of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4. Its bioavailability after subcutaneous injection is approximately 100%. Peak plasma concentration occurs about 1 hour post-dose, and the elimination half-life is roughly 2.7 hours.

P-glycoprotein (P-gp) transport is also not a significant concern. Bremelanotide does not act as a P-gp substrate or inhibitor at clinically relevant concentrations [1]. This profile means the drug is unlikely to alter the absorption or clearance of co-administered medications through the most common drug interaction pathways.

Pharmacokinetic Profile of Finasteride

Finasteride follows a different metabolic route. It is extensively metabolized by CYP3A4, with minor contributions from CYP1A2 and CYP2C9, yielding two major metabolites that carry minimal 5-alpha-reductase inhibitory activity [2]. Oral bioavailability is approximately 80%, and the terminal half-life is 5 to 6 hours in men aged 18 to 60, extending to 8 hours in men over 70 [4].

Because bremelanotide neither inhibits nor induces CYP3A4, it will not alter finasteride plasma concentrations. The reverse is also true. Finasteride's CYP3A4 metabolism does not produce inhibitory or inducing effects on enzymes or transporters relevant to bremelanotide clearance. No published case reports or pharmacokinetic studies have identified a bidirectional interaction between these two drugs.

Pharmacodynamic Considerations: Where the Real Questions Lie

The absence of a pharmacokinetic interaction does not end the clinical analysis. Both drugs influence sexual function through distinct but conceptually related pathways, and this pharmacodynamic dimension deserves attention.

Bremelanotide activates melanocortin-4 receptors (MC4R) in the central nervous system. This activation triggers downstream signaling in hypothalamic circuits involved in sexual arousal and desire [1]. The RECONNECT Phase 3 trials (Study 301, N=1,247 and Study 302, N=1,248) demonstrated a statistically significant increase in desire domain scores on the Female Sexual Function Index (FSFI) compared to placebo, with a mean improvement of 0.5 points on the FSFI desire subscale [5,6].

Finasteride inhibits type II 5-alpha-reductase, blocking the conversion of testosterone to dihydrotestosterone (DHT). DHT plays a role in androgen-dependent tissues, including the prostate, hair follicles, and certain brain regions. In males, finasteride 1 mg daily reduces serum DHT by approximately 70% according to the Propecia label [2]. A subset of men report sexual side effects. The PLESS trial reported decreased libido in 6.4% vs. 3.4% for placebo, erectile dysfunction in 8.1% vs. 3.7%, and decreased ejaculate volume in 3.7% vs. 0.8% over 4 years of follow-up [3].

The pharmacodynamic question becomes clinically interesting in two scenarios. First, could bremelanotide offset finasteride-associated sexual dysfunction? No study has tested this combination, and bremelanotide is FDA-approved only for HSDD in premenopausal women, not for male sexual dysfunction. Off-label use would lack supporting efficacy data. Second, could the combination produce additive mood or neuropsychiatric effects? Both agents act on CNS pathways, though through entirely different receptor systems (MC4R vs. androgen signaling). Post-marketing surveillance for bremelanotide has not flagged synergistic mood effects with 5-alpha-reductase inhibitors [1].

Blood Pressure and Cardiovascular Monitoring

One concrete safety consideration applies to bremelanotide regardless of the co-administered drug. The Vyleesi label carries a warning about transient blood pressure increases. In clinical trials, bremelanotide 1.75 mg subcutaneous caused a mean systolic increase of 6 mmHg and diastolic increase of 3 mmHg, peaking approximately 2 to 3 hours after injection and resolving within 12 hours [1].

Finasteride does not have direct cardiovascular effects. It does not raise or lower blood pressure. Combining the two drugs does not create a compounding hemodynamic risk in the way that bremelanotide combined with an antihypertensive or vasoactive agent might. The Vyleesi prescribing information specifically warns against use in patients with uncontrolled hypertension or known cardiovascular disease due to the transient BP elevation [1]. This warning applies independently of finasteride use.

Patients using bremelanotide should still monitor blood pressure periodically. Any patient with baseline hypertension needs particular attention, whether or not finasteride is in the regimen.

What Major DDI Databases Report

A query of the FDA Adverse Event Reporting System (FAERS) for concurrent bremelanotide-finasteride reports returns no signal as of early 2026. The Lexicomp, Micromedex, and Clinical Pharmacology databases do not list a bremelanotide-finasteride interaction. The Drugs@FDA label for Vyleesi identifies only one named pharmacokinetic interaction: bremelanotide slows the absorption of orally administered naltrexone, reducing its C-max by 50% and delaying T-max by approximately 0.5 hours [1]. The label recommends against concurrent use of bremelanotide with oral naltrexone. Finasteride is not mentioned.

The Vyleesi label also notes that bremelanotide may reduce the systemic exposure of indomethacin, likely through effects on gastric motility [1]. Again, this is a drug-specific interaction unrelated to finasteride.

Clinical Monitoring Recommendations

Even without a formal interaction, co-prescribing any two medications that influence sexual function and CNS pathways calls for structured monitoring. A reasonable clinical approach includes the following.

Baseline assessment before starting either drug. Document sexual function using a validated tool such as the FSFI for female patients or the International Index of Erectile Function (IIEF-5) for male patients. Record baseline blood pressure.

At 4 to 8 weeks after initiation. Re-evaluate sexual function scores. Ask specifically about changes in desire, arousal, and satisfaction. Check blood pressure if bremelanotide is in use.

Ongoing (every 3 to 6 months). Screen for mood changes, including depressive symptoms. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy recommends monitoring mood and psychological well-being in patients on androgen-modulating therapies [7]. While this guideline targets testosterone supplementation specifically, the principle of monitoring extends to any regimen affecting androgen pathways.

If sexual side effects emerge or worsen. Distinguish whether symptoms align with finasteride's known adverse profile (decreased libido, erectile changes) or represent a separate process. Bremelanotide-related adverse events in the RECONNECT trials included nausea (40.0% vs. 1.3% placebo), flushing (20.3% vs. 1.5%), and headache (11.3% vs. 6.3%) [5]. These are distinct from finasteride's sexual side effect pattern and should be easy to differentiate clinically.

Dose Adjustments: Are They Necessary?

No dose adjustment is required for either drug when used concurrently. The Vyleesi dose is fixed at 1.75 mg subcutaneous, administered at least 45 minutes before anticipated sexual activity, with a maximum frequency of once every 24 hours and no more than 8 doses per month [1]. Finasteride dosing is 1 mg daily for androgenetic alopecia or 5 mg daily for BPH [2]. Neither dose needs modification based on the presence of the other drug.

Hepatic impairment changes the picture for finasteride. Finasteride is hepatically metabolized, and the label advises caution in liver disease, though specific dose reductions are not defined [2]. Bremelanotide exposure increases modestly in patients with hepatic impairment (AUC increased 50% in moderate impairment), but the label does not mandate dose reduction [1]. If a patient has hepatic impairment and is taking both drugs, closer monitoring of drug effects and adverse events is prudent even though no formal interaction exists.

Special Populations and Off-Label Contexts

Bremelanotide's approval is limited to premenopausal women with acquired, generalized HSDD not caused by a medical condition, psychiatric disorder, or relationship problem [1]. Finasteride is approved only for men. The clinical overlap between these patient populations is therefore limited in labeled use.

Off-label prescribing introduces different considerations. Some clinicians have explored bremelanotide in postmenopausal women, though the RECONNECT trials excluded this group [5]. Finasteride is occasionally prescribed off-label in women for androgenetic alopecia, typically at 2.5 to 5 mg daily, though it is Category X in pregnancy and requires reliable contraception [8]. A woman taking both bremelanotide and finasteride off-label would need careful counseling about pregnancy avoidance given finasteride's teratogenic risk (abnormal external genitalia in male fetuses exposed in utero).

Transgender patients on feminizing hormone therapy may use finasteride as an adjunct antiandrogen. If bremelanotide were considered in this population, the lack of trial data in transgender women means that efficacy and safety are unknown. Monitoring would need to be individualized.

The Naltrexone Interaction: A More Pressing Concern

For patients focused on drug interactions with Vyleesi, the clinically actionable interaction is with naltrexone, not finasteride. Bremelanotide reduces naltrexone C-max by approximately 50% when both are taken concurrently [1]. This reduction could diminish naltrexone's efficacy in alcohol use disorder or opioid use disorder treatment. The FDA label explicitly recommends against co-administration [1]. Patients using naltrexone for any indication should discuss alternatives with their prescribing clinician before starting bremelanotide.

Bremelanotide has no documented interactions with PDE5 inhibitors (sildenafil, tadalafil), SSRIs, or combined oral contraceptives based on the current labeling [1]. This clean interaction profile is a function of its non-CYP, non-P-gp metabolic pathway.

Counseling Points for Patients

Clinicians prescribing bremelanotide to a patient whose partner uses finasteride, or managing a patient on both agents off-label, should cover three points. First, no pharmacokinetic interaction exists. The drugs do not change each other's blood levels. Second, both drugs can independently affect sexual function: bremelanotide is designed to increase desire, while finasteride may decrease it. Patients should report any changes clearly so the clinician can attribute effects to the correct medication. Third, bremelanotide causes transient nausea in approximately 40% of users, most commonly with the first few doses, and this side effect is unrelated to finasteride [5].

Patients should also know that bremelanotide is self-administered via an autoinjector in the abdomen or thigh. Injection-site reactions occurred in 5.4% of participants in clinical trials [5]. These are local effects with no bearing on finasteride therapy.

The maximum recommended frequency for Vyleesi remains 8 doses per calendar month, with at least 24 hours between injections, regardless of concurrent medications [1].